Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis

Inflammatory Bowel Diseases

Volumn 22, Issue 7, 2016, Pages 1647-1654

  Aloi, Marina ^a   D'Arcangelo, Giulia ^a   Bramuzzo, Matteo ^b   Gasparetto, Marco ^c   Martinelli, Massimo ^d   Alvisi, Patrizia ^e   Illiceto, Maria Teresa ^f   Valenti, Simona ^g   Distante, Manuela ^a   Pellegrino, Salvatore ^g   Gatti, Simona ^h   Arrigo, Serena ⁱ   Civitelli, Fortunata ^a   Martelossi, Stefano ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f SPIRITO SANTO HOSPITAL   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ G GASLINI INSTITUTE   (Italy)

Author keywords

azathioprine; children; mucosal healing; ulcerative colitis

Indexed keywords

AZATHIOPRINE; CALGRANULIN; CORTICOSTEROID; PANCREAS ENZYME; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHILD; CHILDHOOD DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOSCOPY; FECES ANALYSIS; FEMALE; FOLLOW UP; HEALING; HOSPITALIZATION; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MUCOSAL HEALING; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RASH; REMISSION; SEPSIS; SIDE EFFECT; TREATMENT DURATION; ULCERATIVE COLITIS; VOMITING; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; COLON RESECTION; FECES; INTESTINE MUCOSA; MULTICENTER STUDY; PRESCHOOL CHILD; REGISTER; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME FACTOR; WOUND HEALING;

ADOLESCENT; ADRENAL CORTEX HORMONES; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COLECTOMY; COLITIS, ULCERATIVE; FECES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WOUND HEALING;

EID: 84976321890     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000828     Document Type: Article

References (48)

1. Schirbel A, Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis. 2010;11:266-276
2. Aloi M, D'Arcangelo G, Pofi F, et al. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis. 2013;7: 509-515
3. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821-826
4. Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001-2010
5. Cosnes J, Nion-Laurmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241
6. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902
7. Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008; 14:949-954
8. Chhaya V, Saxena S, Cecil E, et al. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther. 2015;41:89-98
9. Chhaya V, Pollok RC, Cecil E, et al. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther. 2015;42:990-999
10. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625
11. Aloi M, Lionetti P, Barabino A, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:597-605
12. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795-806
13. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321
14. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423-432
15. Schroeder K, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629
16. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224
17. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688
18. Ott C, Takses A, Obermeier F, et al. How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort. Int J Colorectal Dis. 2014;29:1329-1338
19. Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis-lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis. 2014;8:1-4
20. Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut. 2014;63:1695-1699
21. Turner D. Relapsing and refractory ulcerative colitis in children. Dig Dis. 2014;32:419-426
22. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012;18:1641-1646
23. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014;63:1607-1616
24. Picco MF, Zubiaurre I, Adluni M, et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating nonstricturing Crohn's disease. Am J Gastroenterol. 2009;104:2754-2759
25. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-1235
26. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine versus conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology. 2013;145:758-765
27. Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology. 2013;145:766-774
28. Pineton Chambrun G, Peyrin-Biroulet L, Lémann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15-29
29. Boal Carvalho P, Dias de Castro F, Rosa B, et al.Mucosal healing in ulcerative colitis-when zero is better. J Crohns Colitis. 2016;10:20-25
30. Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, et al. The impact of endoscopic inflammation and mucosal healing on health-related quality of life in ulcerative colitis patients. J Crohns Colitis. 2015;9: 625-632
31. Villanacci V, Antonelli E, Salemme M, et al. Assessing mucosal healing in ulcerative colitis: the simpler, the better. Endoscopy. 2015;47:759
32. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mildto-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007; 26:205-215
33. Barreiro-Acosta M, Vallejo N, Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis. 2016;10:13-19
34. López-Palacios N, Mendoza JL, Taxonera C, et al. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med. 2011;22:621-625
35. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400
36. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422
37. Actis GC, Pellicano R, David E, et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinicalpractice based forecast. Inflamm Allergy Drug Targets. 2010;9:6-9
38. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53
39. Sandborn WJ, Panés J, Zhang H, et al. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology. 2016;150:96-102
40. Theede K, Kiszka-Kanowitz M, Nielsen AM, et al. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scand J Gastroenterol. 2014;49:418-423
41. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368
42. De Vos M, Dewit O, D'Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012;6:557-562
43. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148:938-947
44. Roth LS, Chande N, Ponich T, et al. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol. 2010;16:232-236
45. Mossop H, Davies P, Murphy MS. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2008;47:123-129
46. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009;104:2080-2088
47. Sood R, Ansari S, Clark T, et al. Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis. 2015;9:191-197
48. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847-858